Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.49 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL689247 | 0.93 | ESR1 (0.46) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| Hx-1171 SCHEMBL688955 | 0.78 | ESR1 (0.50) | ESR1THRBALOX5NR5A1 | |
| Hx-1171 SCHEMBL29375871 | 0.78 | ESR1 (0.50) | ESR1THRBALOX5NR5A1 | |
| SCHEMBL7607111 | 0.78 | THRA (0.48) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL29372751 | 0.75 | ACHE (0.48) | ESR1MEN1HTTKMT2AMAPT | |
| SCHEMBL2562811 | 0.75 | ACHE (0.48) | ESR1MEN1HTTKMT2AMAPT | |
| Methoxymethane SCHEMBL7620185 | 0.73 | CYP3A4 (0.46) | ESR1MEN1THRBHTTKMT2A | |
| Methylhydroquinone SCHEMBL28182360 | 0.73 | ESR1 (0.52) | ESR1MEN1THRBHTTKMT2A | |
| SCHEMBL14015792 | 0.72 | ESR1 (0.58) | ESR1THRBNR5A1 | |
| Catechol SCHEMBL8451493 | 0.71 | MEN1 (0.52) | MEN1THRBHTTKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107530299-A | Chronic respiratory disease therapeutic agent and cardiac fibrosis composite inhibiting | 日本海博克斯股份有限公司 | 2018-01-02 | — | — | CN | claimed |
| EP-2052719-B1 | Curative drug for neurodegenerative diseases | NIPPON HYPOX LAB INC (JP) | 2013-01-16 | — | — | EP | claimed |
| EP-2110127-B1 | Hepatic Fibrosis Inhibitor | NIPPON HYPOX LAB INC (JP) | 2012-02-29 | — | — | EP | claimed |
| CN-101559049-B | Hepatic fibrosis inhibitor | NIPPON HYPOX LAB INC | 2012-02-29 | — | — | CN | claimed |
| US-7847132-B2 | Hepatic fibrosis inhibitor | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 2010-12-07 | — | — | US | claimed |
| US-20100184858-A1 | Hepatic fibrosis inhibitor | BIOTOXTECH CO., LTD (KR) | 2010-07-22 | — | — | US | claimed |
| US-20100160432-A1 | Curative drug for neurodegenerative diseases | SUGIYAMA SATORU | 2010-06-24 | — | — | US | claimed |
| US-20090270654-A1 | HEPATIC FIBROSIS INHIBITOR | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 2009-10-29 | — | — | US | claimed |
| EP-2110127-A1 | Hepatic Fibrosis Inhibitor | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 2009-10-21 | — | — | EP | claimed |
| CN-101559049-A | Hepatic fibrosis inhibitor | NIPPON HYPOX LAB INC (JP) | 2009-10-21 | — | — | CN | claimed |
| EP-2052719-A1 | Curative drug for neurodegenerative diseases | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 2009-04-29 | — | — | EP | claimed |
| US-20090105339-A1 | Curative drug for neurodegenerative diseases | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 2009-04-23 | — | — | US | claimed |
| EP-3287128-A1 | CHRONIC RESPIRATORY DISEASE THERAPEUTIC AGENT AND CARDIAC FIBRILLATION SUPPRESSING COMPOSITION | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 2018-02-28 | — | — | EP | disclosed |
| US-20180049996-A1 | THERAPEUTIC AGENT FOR CHRONIC RESPIRATORY DISEASE AND COMPOSITION FOR INHIBITING CARDIAC FIBROSIS | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 2018-02-22 | — | — | US | disclosed |
| CN-107530299-A | Chronic respiratory disease therapeutic agent and cardiac fibrosis composite inhibiting | 日本海博克斯股份有限公司 | 2018-01-02 | — | — | CN | disclosed |
| EP-2052719-B1 | Curative drug for neurodegenerative diseases | NIPPON HYPOX LAB INC (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-2110127-A1 | Hepatic Fibrosis Inhibitor | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 2009-10-21 | — | — | EP | disclosed |
| CN-101559049-A | Hepatic fibrosis inhibitor | NIPPON HYPOX LAB INC (JP) | 2009-10-21 | — | — | CN | disclosed |
| EP-2052719-A1 | Curative drug for neurodegenerative diseases | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 2009-04-29 | — | — | EP | disclosed |
| US-20090105339-A1 | Curative drug for neurodegenerative diseases | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184858-A1 | Hepatic fibrosis inhibitor | HDGF, HAVCR2, FABP1 | ESR1 4553/4885AKR1C4 585/4885AKR1C3 156/4885 |
| US-20180049996-A1 | THERAPEUTIC AGENT FOR CHRONIC RESPIRATORY DISEASE AND COMPOSITION FOR INHIBITING CARDIAC FIBROSIS | TNNI3, TNNT2, MMP1 | ESR1 4190/4885AKR1C4 1116/4885AKR1C3 592/4885 |
| US-20090105339-A1 | Curative drug for neurodegenerative diseases | HTT, SNCA, NQO1 | ESR1 4628/4885AKR1C4 671/4885AKR1C3 485/4885 |
| US-20100160432-A1 | Curative drug for neurodegenerative diseases | HTT, SNCA, NQO1 | ESR1 4628/4885AKR1C4 671/4885AKR1C3 485/4885 |
| US-20090270654-A1 | HEPATIC FIBROSIS INHIBITOR | HDGF, HAVCR2, FABP1 | ESR1 4553/4885AKR1C4 585/4885AKR1C3 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.